Yossi Gross

Jurny Releases Free, AI-Enhanced Property Management System and Tools Powered by GPT-4

Retrieved on: 
Tuesday, May 16, 2023

LOS ANGELES, May 16, 2023 /PRNewswire/ -- Jurny, Inc., a pioneering hospitality tech company powering operations for short-term rental (STR) properties across the globe, is rolling out its latest and most robust operating system to date. Available now, JurnyOS 2.0 is powered by GPT-4 and features dynamic AI tools designed to connect, optimize and automate operational tasks and guest management.

Key Points: 
  • Available now, JurnyOS 2.0 is powered by GPT-4 and features dynamic AI tools designed to connect, optimize and automate operational tasks and guest management.
  • Premier Management in a Free PMS - Jurny now offers the industry's only completely free PMS leveraging generative AI to assist hosts with managing their properties.
  • All-in-One Vertically Integrated System - Remove the hassle of finding the best tools and say goodbye to tracking multiple licenses and renewal dates.
  • In 2019, he and his team launched Jurny to fix the fragmented and costly property management model through modern, transformative technologies.

Issuu Expands Leadership Team with Key Hires and Promotions

Retrieved on: 
Wednesday, September 15, 2021

Grosse is returning to lead a combined engineering and product design team and help compound Issuu's accelerating growth.

Key Points: 
  • Grosse is returning to lead a combined engineering and product design team and help compound Issuu's accelerating growth.
  • Prior to his original tenure at Issuu, he served as Vice President of Engineering at SoundCloud, where he built the engineering team from 20 engineers to 100 in over four locations around the globe.
  • Further expanding Issuu's executive leadership team, Audrey Vandenbroeck, formerly Issuu's Senior Director of Customer Success, has been promoted to Vice President.
  • Vandenbroeck has led the customer success team at Issuu for the last four years.

BlueWind Medical Strengthens Board of Directors with appointment of Kerry Nelson

Retrieved on: 
Tuesday, December 22, 2020

PARK CITY, Utah and BOSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- BlueWind Medical , a medical device company developing minimally invasive neurostimulation devices, announced today the appointment of Kerry Nelson to the companys Board of Directors.

Key Points: 
  • PARK CITY, Utah and BOSTON, Dec. 22, 2020 (GLOBE NEWSWIRE) -- BlueWind Medical , a medical device company developing minimally invasive neurostimulation devices, announced today the appointment of Kerry Nelson to the companys Board of Directors.
  • Nelson is a successful medical device investor and fund manager who has launched and managed healthcare focused investment funds.
  • She joins Directors Ilan Neugarten and Yossi Gross, both of Rainbow Medical, and Chairman and CEO Dan Lemaitre, on the board.
  • We are pleased to welcome Kerry to the Board of Directors.

Mainstay Medical Announces U.S. FDA Approval of ReActiv8® Neurostimulation System for Chronic Low Back Pain

Retrieved on: 
Monday, June 22, 2020

Mainstay Medical Holdings plc (Mainstay or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved the Companys Premarket Approval (PMA) application for ReActiv8, its implantable neurostimulation system to treat intractable chronic low back pain.

Key Points: 
  • Mainstay Medical Holdings plc (Mainstay or the Company) today announced that the U.S. Food and Drug Administration (FDA) has approved the Companys Premarket Approval (PMA) application for ReActiv8, its implantable neurostimulation system to treat intractable chronic low back pain.
  • We are thrilled to receive FDA approval of ReActiv8, which is designed to be a restorative treatment and represents a new option for patients suffering with chronic low back pain.
  • I have seen ReActiv8 provide durable improvements in back pain, the disabling effects of back pain, and quality of life.
  • Mainstay Medical Holdings is a medical device company focused on commercializing an innovative implantable restorative neurostimulation system, ReActiv8, for people with disabling Chronic Low Back Pain (CLBP).

VisionCare, Inc. Announces CE Mark Approval of the Tsert-SI™ Delivery System for the CentraSight Treatment Program

Retrieved on: 
Monday, May 11, 2020

VisionCare, Inc. ("VisionCare), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that receipt of a Conformit Europene (CE) Mark for the Tsert-SI delivery system for the CentraSight treatment program.

Key Points: 
  • VisionCare, Inc. ("VisionCare), a developer of advanced visual prosthetic devices for the treatment of age-related macular degeneration (AMD), today announced that receipt of a Conformit Europene (CE) Mark for the Tsert-SI delivery system for the CentraSight treatment program.
  • The CentraSight treatment program includes the Implantable Miniature Telescope (by Dr. Isaac Lipshitz), which is available around the world, including the United States, Europe, Australia, New Zealand, and Israel.
  • The Tsert-SI delivery system includes a pre-loaded telescope implant injector, which only requires a 6.5mm incision, reducing the incision size by nearly half.
  • Patients and physicians can find more information about the telescope implant and related treatment program by visiting www.CentraSight.com or calling 1-877-997-4448.